



AMP 2025 Committee and Subdivision Annual Reports

Board of Directors

President	Jane S. Gibson, Ph.D.
President-Elect;	Aaron D. Bossler, M.D., Ph.D.
Awards and Strategic Opportunities Committee Chair	
Past President and Nominating Committee Chair	Maria E. Arcila, M.D.
Secretary-Treasurer and Finance Committee Chair	Yasmine M.N. Akkari, Ph.D.
Clinical Practice Committee Chair	Alanna Church, M.D.
Economic Affairs Committee Chair	Jay Patel, M.D.
International Affairs Committee	Rami Mahfouz, M.D., MPH
Membership Affairs Committee Chair	Jennifer Morrissette, Ph.D.
Professional Relations Committee Chair	Eric Konnick, M.D., M.S.
Program Committee Chair	Somak Roy, M.D.
Publication & Communication Committee Chair	Patricia Tsang, M.D.
Training & Education Committee Chair	Marjorie David, M.D., M.S.
Genetics Subdivision Chair	Kristy Crooks, Ph.D.
Hematopathology Subdivision Chair	Rena R. Xian, M.D.
Infectious Diseases Subdivision Chair	Joseph D.C. Yao, M.D.
Informatics Subdivision Chair	Julie Hirschhorn, Ph.D.
Solid Tumors Subdivision Chair	Anthony N. Snow, M.D.
Early Career Member	Adam Fisch, M.D., Ph.D.
Early Career Member	Emilia Calvaresi, M.D., Ph.D.
Chief Executive Officer	Laurie S. Menser, CAE

AMP Awards Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair	Aaron D. Bossler, M.D., Ph.D.
Member	Margaret Gulley, M.D.
Member	Shelby Melton, M.D.
Member	Shi Yang, M.D.
Member	Anna Yemelyanova, M.D.
Member (<i>Ex Officio</i> – President)	Jane S. Gibson, Ph.D.
Member (<i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

PURPOSE SUMMARY:

The Awards Committee consists of 5 members (4 appointed) who oversee the nomination and selection of the recipient of the Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award, and, if determined applicable, the recipient(s) of the Meritorious Service Award(s). The Committee evaluates the current awards, addresses the need for new awards, and conducts the formal nomination process for potential award recipients.

The President-Elect serves as the Chair of the Awards Committee. The remaining 4 committee members are appointed by the Board for a two-year, renewable term, up to a maximum of six years. The annual selection of 2 incoming committee members is conducted by the committee and the candidates' names are brought forward for Board approval and appointment.

Timeline for AMP Awards

The Awards Committee coordinated the timing of the AMP recognition awards as follows:

- Ongoing: Nominations from the Board, Committees, and Membership
- April: Review and selection by Awards Committee
- April through May: Notification of recipients
- May through September: Assess need for new recognition awards, if any

Selected Award Recipients

- 2025 Jeffrey A. Kant Leadership Award: Alexis B. Carter, MD
- 2025 Meritorious Service Award: Dara L. Aisner, MD, PhD and Lawrence Jennings, MD, PhD
- 2027 Award for Excellence in Molecular Diagnostics: To be announced in Spring 2027

AMP Clinical Practice Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair	Alanna Church, M.D.
Genetics Subdivision Representative	Jennifer Laffin, Ph.D.
Genetics Subdivision Representative	Molly Schroeder, Ph.D.
Hematopathology Subdivision Representative	Susan Harley, M.D.
Hematopathology Subdivision Representative	Peng Wang, M.D., Ph.D.
Infectious Diseases Subdivision Representative	Meghan Starolis, M.S., Ph.D.
Infectious Diseases Subdivision Representative	Mark D. Gonzalez, Ph.D.
Informatics Subdivision Representative	Andrea Sboner, Ph.D.
Informatics Subdivision Representative	Thomas D. Lee, M.D., Ph.D.
Solid Tumors Subdivision Representative	Lauren Ritterhouse, M.D., Ph.D.
Solid Tumors Subdivision Representative	Nikoletta Sidiropoulos, M.D.
Junior Member	Igor Odintsov, M.D.
Junior Member	David Twa, M.D., Ph.D.
Member (<i>Ex Officio</i> – President)	Jane S. Gibson, Ph.D.
Member (<i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

PURPOSE SUMMARY:

The Clinical Practice Committee (CPC) is comprised of AMP members with expertise in one or more of the molecular specialties: infectious diseases, hematopathology, solid tumors, genetics, and informatics. Its purpose is to address the challenges of clinical laboratories and, therefore, improve the service we provide. The AMP Clinical Practice Guidelines Program is comprised of multiple AMP-led working groups that plan, organize, and coordinate efforts such as practice guidelines, sample exchanges, reporting surveys, validation and quality control measures, and advocate for policies that will advance the practice of high quality clinical molecular pathology services. The majority of these projects include representation from other professional organizations and groups. AMP's External Representatives Program additionally fosters collaboration by providing AMP subject matter experts to clinical practice projects led by other professional organizations and groups.

2025 ACTIVITIES:

Publications

- ***Developing Consensus for a More Provider-Friendly Next Generation Sequencing Molecular Biomarker Report: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.*** Available online ahead of publication in the *Journal of Molecular Diagnostics*. Jane Gibson (Chair), Hanadi El Achi (CAP representative), Dana Altenburger (CAP representative), Noah Brown, Amy S. Clark (ASCO representative), Joshua Coleman, Rajyasree Emmadi, Amber M. Fussell, Meera Hameed, Danielle Jordan, Jennifer Laudadio, Anthony Provenzano (ASCO representative), Robyn L. Temple-Smolkin, and Christopher G. Suci. DOI: <https://doi.org/10.1016/j.jmoldx.2025.08.011>.
- ***Recommendations for Clinical Molecular Laboratories for Detection of Homologous Recombination Deficiency in Cancer: A Joint Consensus Recommendation of the Association of Molecular Pathology, Association of Cancer Care Centers, and College of American Pathologists.*** Published in the August 2025 issue of the *Journal of Molecular Diagnostics*. Susan J. Hsiao (Chair), Destin Black (ACCC representative), Kelly A. Devereaux, Ian S. Hagemann (CAP representative), Lawrence J. Jennings, Diana Mandelker, Vera A. Paulson, Michelle Shiller, Tracy L. Stockley, Eric Vail, Praveen Vikas (ASCO representative), and Anna Yemelyanova. DOI: <https://doi.org/10.1016/j.jmoldx.2025.05.003>.
- ***Development of a Body of Knowledge for the Clinical Bioinformatician: Perspectives from the Association for Molecular Pathology's Clinical Bioinformatician Body of Knowledge Steering***

Committee. Published in the July 2025 issue of the *Journal of Molecular Diagnostics*. Somak Roy (Chair), Amber M. Fussell, Danielle Jordan, Sabah Kadri, Annette Leon, Ryan J. Schmidt, Robyn L. Temple-Smolkin, and Jason D. Merker. DOI: <https://doi.org/10.1016/j.jmoldx.2024.12.002>.

- **Clinical Bioinformatician Body of Knowledge—Molecular Diagnostics Core: A Report of the Association for Molecular Pathology.** Published in the July 2025 issue of the *Journal of Molecular Diagnostics*. Annette Leon (Chair), Eduardo Castro-Echeverry, Amber M. Fussell, Danielle Jordan, Nefize S. Kip, Angshumoy Roy, Carlos J. Suarez, Robyn L. Temple-Smolkin, and Joshua Coleman. DOI: <https://doi.org/10.1016/j.jmoldx.2025.03.006>.
- **Clinical Bioinformatician Body of Knowledge—Bioinformatics and Software Core: A Report of the Association for Molecular Pathology.** Published in the July 2025 issue of the *Journal of Molecular Diagnostics*. Sabah Kadri (Chair), Kelly E. Craven, Amber M. Fussell, Elaine P.S. Gee, Danielle Jordan, Eric W. Klee, Niklas Krumm, Robyn L. Temple-Smolkin, Ahmet Zehir, Weiwei Zhang, and Andrea Sboner. DOI: <https://doi.org/10.1016/j.jmoldx.2025.04.008>.
- **Clinical Bioinformatician Body of Knowledge—Clinical Laboratory Regulation and Data Security Core: A Report of the Association for Molecular Pathology.** Published in the July 2025 issue of the *Journal of Molecular Diagnostics*. Ryan J. Schmidt (Chair), Larissa V. Furtado, Amber M. Fussell, Danielle Jordan, Matthew Lebo, Aijazuddin Syed, Robyn L. Temple-Smolkin, Eric Venner, Elizabeth Worthey, and Alexis B. Carter. DOI: <https://doi.org/10.1016/j.jmoldx.2025.04.003>.
- **Considerations for SARS-CoV-2 Genomic Surveillance: A Joint Consensus Recommendation of the Association for Molecular Pathology and Association of Public Health Laboratories.** Published in the January 2025 issue of the *Journal of Molecular Diagnostics*. Julie W. Hirschhorn, N. Esther Babady, Allen Bateman (APHL representative), Heather M. Blankenship (APHL representative), Jennifer Dien Bard, Kelsey Florek (APHL representative), Paige M.K. Larkin, Marie-Claire Rowlinson (APHL representative), Kelly Wroblewski (APHL representative), and Donna M. Wolk. AMP project management provided by Danielle Jordan and Mary Williams. DOI: <https://doi.org/10.1016/j.jmoldx.2024.09.005>.

Additional Accomplishments

- Multiple AMP working group projects are underway.
- One new project launched; additional projects are launching soon.
- Assisted AMP Advocacy committees and the various Subdivisions with input for their various initiatives where applicable.
- Multiple AMP Associate Members are working on CPC working groups as Junior Members.

Requests from the CPC

- We encourage all AMP members to alert the Board or appropriate committees when laboratory guidelines or recommendations are opened for public comment.
- We encourage AMP members to actively contribute to calls for information from the CPC.
- Suggestions from AMP members for new CPC initiatives are always welcome! Visit <https://www.amp.org/clinical-practice/clinical-practice-overview/> for more details or email ampclinicalpractice@amp.org.

AMP Clinical Practice Guidelines Program

Working Group / Task Force	Members
NGS Utility for Assessment of T/B-cell Clonality	David Viswanatha (Chair), Keyur Patel, Maria Arcila, Timothy Greiner, Joseph Khoury (CAP representative), David Wu, Devon Chabot-Richards (SH representative), and Habibe Kurt
Molecular MRD Monitoring in Acute Myeloid Leukemia	Keyur Patel (Chair), Noah Brown, Marian Harris, Rashmi Goswami, Annette Kim, Rena Xian (CAP representative), David Wu (SH representative), Hong Fang, Nikhil Patkar, Dale Bixby, and Harrison Tsai

Homologous recombination deficiency (HRD) assessment using next generation sequencing (NGS)	Susan Hsiao (Chair), Lawrence Jennings, Diana Mandelker, Vera Paulson, Michelle Shiller, Tracy Stockley, Eric Vail, Anna Yemelyanova, Destin Black (ACCC representative), Ian Hagemann (CAP representative), Praveen Vikas (ASCO representative), and Kelly Devereaux
CAP/ IASLC/AMP Molecular Testing Guideline for Selection of Lung Cancer Patients for <i>EGFR</i> and <i>ALK</i> Tyrosine Kinase Inhibitors – Revision	Neal Lindeman (AMP Co-Chair), Maria Arcila, David Kwiatkowski, Lynette Sholl, Laura Tafe, and Dhananjay Chitale
Validation of Next-Generation Sequencing Panels for Gene Fusion and Splice Variant Detection	Laura Tafe (Chair), Alanna Church (Co-Chair), Eduardo Castro-Echeverry, Marjorie David, Suneel Kamath (ASCO representative), Michael Kluk, Ravindra Kolhe (CAP representative), Christian Kunder, Andres Madrigal, Fatimah Nahhas, and Valentina Nardi
Update of “Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists”	Marilyn Li (Chair), Cindy Vnencak-Jones (Co-Chair), Amir Behdad, Ozge Ceyhan-Birsoy (ACMG representative), Catherine Cottrell, Eric Duncavage, Melissa Gildenberg, Obi Griffith (CGC representative), Annette Kim (SH representative), Shashikant Kulkarni (ClinGen Cancer Variant Interpretation representative), Christine Lovly (ASCO representative), Jason Rosenbaum, Somak Roy, Eytan Stein (ASH representative), Lea Surrey (CAP representative), Scott Turner, and Kai Wang
Oncologist-friendly Biomarker Reporting	Jane Gibson (Chair), Dana Altenburger (CAP representative), Noah Brown, Amy Clark (ASCO representative), Joshua Coleman, Hanadi El Achi (CAP representative), Rajyasree Emmadi (Ex-Officio), Meera Hameed, Jennifer Laudadio, Anthony Provenzano (ASCO representative), and Christopher Suci
Patient-friendly Biomarker Reporting	Rajyasree Emmadi (Chair), Allison Cushman-Vokoun, Jane Gibson, Julie Hirschhorn, Jennifer Morrisette, Irene Newsham, Sinchita Roy Chowdhuri, and Eric Vail
Standardization of Clinically Relevant Pharmacogenetic Alleles (PGx) Overview	Karen Weck (Chair), Victoria Pratt (Co-Chair), Makenzie Fulmer, Andrea Gaedigk (PharmVar representative), Houda Hachad, Yuan Ji (ACMG representative), Lisa Kalman, Reynold Ly, Ann Moyer (CAP representative), Stuart Scott, Amy Turner, Ron van Schaik (DPWG and ESPT representative), and Michelle Whirl-Carrillo (CPIC and PharmGKB representative)
ICC-WHO Classifications Hematopathology Subdivision Leadership Task Force	Eric Duncavage (Chair), Rena Xian (Co-Chair), Noah Brown, Valentina Nardi, Mark Ewalt, Amir Behdad, Pawel Mroz, Joanna Conant, and Jennifer Bynum
Clinical Validation of cfDNA and ctDNA Assays	Panieh Terraf (Chair), Christina Lockwood (Co-Chair), Navid Sadri, Rena Xian, Henning Stehr, Shamini Selvarajah, Pawel Mroz, Thuy Phung, Venkata Yellapantula, Christian Rolfo (ISLB representative), Mark Ewalt (CAP representative), and Samuel Harvey
Best Practice Guidance for AI and ML for Molecular Diagnostics Part 1	Jeffrey Gagan (Chair), Andrea Sboner (Co-Chair), Jamal Benhamida, Emilia Calvaresi, Samuel Harvey, Eric Klee, Thomas Lee, Annette Leon, Gwendolyn McMillin (ADLM representative), Pawel Mroz (CAP representative), and Weiwei Zhang

AMP External Representatives Program

AMP Representative	Lead Organization(s); Other Collaborating Organization(s)	Workgroup / Committee
Ravindra Kolhe	American College of Medical Genetics and Genomics (ACMG)	Points to Consider for the Clinical Validation and Implementation of Optical Genome Mapping
Jianling Ji Matija Snuderl	ACMG	Points to Consider for the Implementation of DNA Methylation Arrays for Clinical Diagnostics
Carolyn Sue Richards	ACMG	Incidental Findings in Inherited Diseases Update Workgroup
Scott Turner	ACMG; American Society of Human Genetics (ASHG), Cancer Genomics Consortium (CGC), EMQN, HUGO Gene Nomenclature Committee	Technical Laboratory Standards for Interpretation and Reporting of Acquired Copy-number Abnormalities and Copy-neutral Loss of Heterozygosity in Neoplastic Disorder
Alanna Church	ACMG; College of American Pathologists (CAP), CGC, International Society for the Study of Vascular Anomalies (ISSVA)	Vascular Anomalies and Somatic Overgrowth Disorders
Julie Gastier-Foster Scott Topper	ACMG; ClinGen, CAP	Interpretation of Sequence Variants Update Workgroup
Shashirekha Shetty	ACMG; ClinGen, CAP	2020 ACMG/ClinGen Technical Standards for Interpretation and Reporting of Constitutional Copy Number Variants (CNVs) Workgroup
Somak Roy Fei Dong	ACMG; ClinGen, CAP, HUGO Gene Nomenclature Committee with representation from EMQN and Association for Clinical Genomic Science	Technical Standards for the Reporting and Sharing of Interpreted Genomic Variation in Journals Workgroup
Marco Leung Zehra Ordulu	ACMG	Use of Sex and Gender Identifiers in Clinical and Laboratory Genetics and Genomics Workgroup
Marjorie David	American College of Surgeons American Joint Committee on Cancer (ACS AJCC)	Education Committee; AMP is a Member Organization
Matthew Smolkin	ACS AJCC	American Joint Committee on Cancer 2025 Annual Meeting
Eric Duncavage	Association of Community Cancer Centers (ACCC)	Advisory Committee
Dara Aisner Sinchita Roy- Chowdhuri	ACCC	Operational Pathways in Lung Cancer
Michelle Shiller	ACCC	Cancer Diagnostics Advisory Committee
Rena Xian	American Society of Clinical Oncology (ASCO)	Cell-free DNA Testing Guideline Expert Panel
Dara Aisner	ASCO	Multi-Site Guideline Advisory Group

Laura Tafe		
Kristy Crooks	American Society of Pharmacovigilance	Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Robyn Temple-Smolkin	BLOODPAC	Clinician Education & Access Working Group
Aatur Singhi	BLOODPAC	Early Cancer Detection and Screening Working Group
Timothy O'Leary	BLOODPAC	MRD/Multi-Cancer Early Detection Recommended Data Elements Working
Michael Dorschner	BLOODPAC	MRD Clinical Validation Working Group
Jacquelyn Reuther	BLOODPAC	bTMB Analytical Validation Working Group
Rina Kansal	BLOODPAC	CHIP Working Group
Bing Melody Zhang	BLOODPAC	Molecular Residual Disease (MRD) Analytical Validation Working Group
Richard Hickman	BLOODPAC	CSF Brain Tumor Working Group
Christina Lockwood	BLOODPAC	Advisory Committee, Analytical Validation Working Group, and Minimal Data Elements Working Group
Sanja Dacic	Cancer Support Community (CSC)	Lung Biomarker Digital Tool Advisory Board
Mehdi Nassiri	Centers for Disease Control and Prevention (CDC)	Forum on Adoption of Standards for Laboratory Data Exchange and Interoperability
Robyn Temple-Smolkin	CDC	Surge Capacity MOU Partners; AMP is a Member Organization
Marilyn Li	ClinGen	Somatic Cancer Clinical Domain Workgroup
Daniel Jones	Clinical Laboratory Improvement Advisory Committee	Next Generation Sequencing Best Practices Forum
Somak Roy	Clinical Laboratory Standards Institute (CLSI)	Document Development Committee on Sequencing Bioinformatics for Human Genetics and Oncology (MM25) work group
Christina Lockwood	CLSI	Document Development Committee on Liquid Biopsy Methods for Oncology (MM28) work group
Daniel Sabath	College of American Pathologists (CAP)	Molecular Oncology Committee
Ryan Schmidt Susan Hsiao	CAP	Genomic Medicine Resource Committee
Ryan Schmidt	CAP	Clinical Grade HGVS Workgroup

Betsy Bove	CAP; ACMG	Pharmacogenomics (PGx) Sub-committee of the Biochemical and Molecular Genetics Committee (BMGC) Workgroup
Mark Ewalt	CAP; International Clinical Cytometry Society	Evaluation of Minimal Residual Disease in Acute Lymphoblastic Leukemia Guideline workgroup
Mehdi Nassiri	Food and Drug Administration (FDA) Systemic Harmonization and Interoperability Enhancement for Laboratory Data (SHIELD)	SHIELD Consortium
Robyn Temple-Smolkin	FDA SHIELD	SHIELD Steering Committee; AMP is a Member Organization
Maria Bettinotti	Foundation for the National Institutes of Health (FNIH)	Biomarkers Consortium Steering Committee for Inflammation and Immunity
Snehal Patel	FNIH	Biomarkers Consortium Steering Committee for Cancer
Jing Xu	FNIH	Steering Committee for Cancer: Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) work group
Alanna Church	From Testing to Targeted Treatments (FT3)	"From Availability to Patient Access and Improving Patient Outcomes: Scaling What Works in Precision Medicine" FT3 Community of Practice Meeting, Berlin, Germany
Mary Beth Beasley	LUNGevery	Initiate Reflex Testing in NSCLC Workgroup
Robyn Temple-Smolkin	LUNGevery	Guideline Statement Workgroup
Robyn Temple-Smolkin	National Human Genome Research Institute (NHGRI)	Genomics-Enabled Learning Health System Network (gLHS) Steering Committee
Maria Arcila	Personalized Medicine Coalition	Steering Committee for Precision Oncology Roadmap
Yaolin Zhou Joshua Deignan	Test Renaming for Understanding and Utilization (TRUU-Lab) coalition	Steering Committee
Valentina Nardi	Variant Interpretation for Cancer Consortium (VICC)	Gene Fusion Oncogenicity Work Group
Panieh Terraf	Variant Interpretation for Cancer Consortium (VICC)	Gene Fusion Curation Working Group
Emelia Calvaresi	National Institute of Standards and Technology (NIST)	Genome in a Bottle Steering Committee
Antonia Sepulveda	World Health Organization International Agency for Research on Cancer (WHO IARC)	International Collaboration for Cancer Classification and Research (IC3R)

AMP Economic Affairs Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair	Jay L. Patel, M.D.
Vice Chair, Coverage- Infectious Disease	Erin Graf, Ph.D.
Vice Chair, Coverage- Genetics and Oncology	Eric Vail, M.D.
Vice Chair, New Codes & Pricing (Genetics Subdivision Rep.)	Victoria Pratt, Ph.D.
Member (Informatics Subdivision Rep.)	Nicholas Bevins, Ph.D.
Member	Clarisa Blattner, BS, CPC
Junior Member	Molly Broache, DNP, RN, WHNP-BC
Member	Jay Brock, Ph.D.
Member	Maude Champagne, MBA
Member	Lloyd Hutchinson, M.D.
Member	Rina Kansal, M.D.
Member	Medhi Nassiri, M.D.
Member	Ankita Patel, Ph.D.
Member	Keyur Patel, M.D., Ph.D.
Member	Salvatore Priore, M.D., Ph.D.
Member	Navid Sadri, M.D., Ph.D.
Member	Jennifer Sanmann, Ph.D.
Member	Michelle Schoonmaker, Ph.D.
Member	Ester Stein, MBA
Member	Sarah Rapisardo, Ph.D.
Member (Hemepath Subdivision Rep.)	Patricia Tsang, M.D.
Member (Solid Tumor Subdivision Rep.)	Heather Williams, M.D.
Member (Infectious Disease Subdivision Rep.)	Joseph Yao, M.D.
Junior Member	Jessica Williams, M.D.
Member	Wei Zhang M.D., Ph.D.
Committee Advisor and Member (<i>Ex Officio</i> – President Elect)	Aaron D. Bossler, M.D., Ph.D.
Committee Advisor	Samuel K. Caughron, M.D.
Committee Advisor	Pranil Chandra, DO
Committee Advisor	Jan A. Nowak, M.D., Ph.D.
Member (<i>Ex Officio</i> – President)	Jane S. Gibson, Ph.D.
Member (<i>Ex Officio</i> – PRC Chair)	Eric Konnick, M.D., MS
Member (<i>Ex Officio</i> – Past President)	Maria E. Arcila, M.D.
Member (<i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

PURPOSE SUMMARY:

The Economic Affairs Committee (EAC) addresses, advises, and educates the AMP Board of Directors, membership, payors, legislators, and the public on economic issues of importance to the field of molecular pathology; prepares documents of importance to the Centers for Medicare & Medicaid Services (CMS); and develops and advocates for sound economic policies that promote the availability to patients of high-quality molecular pathology services. The Committee's scope encompasses short and long-term issues associated with the coding for molecular procedures, utilization of and coverage for molecular pathology, the determination of test pricing, and the potential economic impact of public policy decisions on molecular pathology practice. The Committee interacts with the American Medical Association (AMA), the College of American Pathologists (CAP), and other interested organizations in order to achieve common goals.

2025 ACTIVITIES:

The Centers for Medicare and Medicaid Services (CMS) have increasingly denied coverage and/or reduced payment for many medically necessary molecular pathology tests. These restrictions create a challenging environment for clinical practice and for innovators to translate new genomic discoveries into clinical applications. AMP employs government relations consultants, Jennifer Leib, Megan Anderson Brooks, and Lindsey Trischler of Innovation Policy Solutions, to advise the EAC on advocacy strategies and assist with fostering relationships between AMP, key federal agencies, and Congressional offices. Additionally, the EAC is supported by AMP Director, Public Policy and Advocacy, Annie Scrimenti, and AMP Policy Manager, Samantha Pettersen. AMP continues to work with the broader professional community to address policy challenges and opportunities to engage and inform payors who aim to achieve rightful reimbursements for appropriate patient care services.

Leadership:

The Economic Affairs Committee is led by **Jay Patel, M.D.**, who serves as Chair of the committee.

Victoria (Vicky) Pratt, Ph.D., Vice Chair, New Codes & Pricing Subcommittee

Erin Graf, Ph.D., Vice Chair, Coverage Infectious Diseases,

Eric Vail, M.D., Vice Chair, Coverage, Genetics & Oncology

Key Focus Issues:

The Protecting Access to Medicare Act (PAMA)

The Protecting Access to Medicare Act of 2014 (PAMA) required laboratories that perform clinical diagnostic laboratory tests to report the amounts they are paid by private insurers for said tests to the Centers for Medicare and Medicaid Services (CMS). CMS then set the Medicare payment rates for laboratory tests paid under the Clinical Laboratory Fee Schedule (CLFS) based on the weighted median of the private payor data. Since 2014, AMP has continued to express significant concerns to CMS and

Congress on various occasions about issues with the first PAMA exercise and how rates were established (e.g., data entity and reporting entities).

In early 2020, the Laboratory Access for Beneficiaries (LAB) Act was passed by Congress. The LAB Act was supported by AMP and addressed some of AMP's and other stakeholders' concerns with PAMA. It delayed the next round of data reporting until 2021 and delayed the timing for payment reductions under PAMA. Additionally, the LAB Act authorizes Medicare Payment Advisory Committee (MedPAC) to study the methodology CMS used to rate-set through PAMA.

Since the passage of the LAB Act, three additional pieces of legislation were passed: the Coronavirus Aid, Relief, and Economic Security Act (CARES Act; to address the COVID-19 public health crisis) included an additional one-year delay to PAMA and the Protecting Medicare and American Farmers from Sequester Cuts Act, which was passed in December 2021, also included an additional one-year delay to PAMA. The Consolidated Appropriations Act of 2023 was passed in December 2022. This revised the phase-in of payment reductions under the Medicare private payor rate-based CLFS. Statutory phase-in of payment reductions is extended through calendar year (CY) 2026. This created a 0.0 percent reduction for CY 2023 and determined that payment may not be reduced by more than 15 percent for CYs 2024 through 2026. On September 25th, 2024, a continuing resolution passed that included another one-year delay in PAMA cuts and reporting. Following these actions, the next PAMA reporting cycle will begin in 2026.

In Fall 2025, AMP met with House Committees of jurisdiction, Energy and Commerce and Ways and Means to discuss long-term PAMA solutions including the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.

The RESULTS Act (S. 2761 / H.R. 5269) legislative option is heralded by ACLA. The RESULTS Act would reform PAMA by reducing the reporting by laboratories for widely available tests. While reducing the administrative and reporting burden on clinical laboratories on tests that do not meet the widely available test definition. Importantly, this legislation would also address steep payment cuts of up to 15% on approximately 820 widely used tests that are scheduled to begin January 1, 2026.

Clinical Lab Fee Schedule for Calendar Year 2026

During the summer, AMP provided written and oral comments to CMS on the Calendar Year (CY) 2026 Clinical Lab Fee Schedule (CLFS). **Dr. Victoria Pratt** represented AMP at the annual CLFS meeting on June 27, 2025. She presented crosswalk recommendations for the new and reconsidered CY2026 CLFS molecular pathology, genomic sequencing, optical genome mapping, and microbiology procedures.

Additionally, in July 2025, AMP also attended the Clinical Laboratory Diagnostic Tests (CDLTs) Public meeting at CMS headquarters, where the Advisory Panel (the Panel) on CDLTs reviewed and voted on crosswalk/gapfill pricing for new and reconsidered codes. The Panel was established by PAMA and advises CMS on various issues under PAMA including payment rates for new tests, including whether to

use the crosswalk or gapfill methodology for initial price determination. **Dr. Pranil Chandra** serves on the panel, nominated by AMP.

In late September, CMS released the CY2026 CLFS Preliminary Determinations for the new and reconsidered services. While a majority of the preliminary CMS determinations align with AMP and other laboratory organizations' recommendations, a few of the preliminary recommendations provided by CMS vastly differ from both the Advisory Panel and AMP recommendations, along with stakeholder input and, in many cases, do not represent the best options for crosswalks. AMP submitted comments reiterating our recommendations. Pricing determinations will be finalized later this year.

Medicare and Private Payer Coverage Policies

Monitoring emerging policies continued to be a major focus of the Coverage subcommittee led by **Dr. Erin Graf and Dr. Eric Vail**. AMP continues to advocate with CMS regarding coverage policy actions taken by Medicare Administrative Contractors (MACs). As of October 10, 2025, AMP has provided responses to various MACs for approximately 16 draft local coverage determinations (dLCDs). AMP and the College of American Pathologists (CAP) frequently collaborate and draft joint responses. The EAC is very thankful to the AMP members that have volunteered their time and subject matter expertise to assist in responding to the diverse coverage policy issues.

Additionally, earlier in 2025, AMP responded to one private payer coverage policy: Elevance Health Lab.00026 Systems Pathology and Multimodal Artificial Intelligence Testing for Cancerous and Precancerous Conditions. This policy had unclear language that could cause non-coverage of decision support tools. AMP proposed alternative language, and it was adopted by Elevance Health.

AMP also continues to meet with MoDx (administered by Palmetto GBA), as their policies are adopted by multiple MACs and affect a large percentage of AMP members. EAC leadership met with MoDx to discuss their policies and how we can collaborate in the future to make sure that AMP members' concerns are addressed. AMP continues to meet with MoDx to address various issues important to AMP members

CPT Codes

The EAC New Codes and Pricing Subcommittee, led by **Dr. Victoria Pratt**, advises and reviews new CPT code applications submitted to the Pathology Coding Caucus (PCC) and the Molecular Pathology Advisory Group (MPAG). **Dr. Samuel Caughron** continues to represent AMP as a voting member on the PCC. His voting is supported by the expertise and input from the New Codes Subcommittee. Throughout the year, the Subcommittee may submit new CPT code change proposals to AMA based on member need and input. The subcommittee also provided input to CMS' National Correct Coding Initiative (NCCI) to help ensure national correct coding methodologies of procedure to procedure (PTP) and medically

unlikely edits (MUEs) for molecular procedures and is working with a broad group of stakeholders to address issues with updates to the NCCI manual.

Outside Organization Involvement

- **Dr. Aaron Bossler** serves on the CPT Editorial Panel
- **Dr. Victoria Pratt**, Dr. Victoria serves as Co-Chair on the AMA Proprietary Laboratory Analyses Technical Advisory Group (PLA-TAG) and **Drs. Joseph Yao, Aaron Bossler** serve as members of the PLA-TAG.
- **Dr. Samuel Caughron** serves on the PCC, with **Dr. Keyur Patel** serving as the technical advisor.
- **Dr. Keyur Patel** serves as an AMP representative on the AMA Molecular Pathology Advisory Group (MPAG) which also includes AMP members **Drs. Aaron Bossler, Ann Moyer, Madhuri Hegde, and Victoria Pratt.**

AMP Finance Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair	Yassmine M.N. Akkari, Ph.D.
President	Jane S. Gibson, Ph.D.
President-Elect	Aaron D. Bossler, M.D., Ph.D.
Past President	Maria E. Arcila, M.D.
Member	Lynne V. Abruzzo, M.D., Ph.D.
Member	Shelby Melton, M.D.
Member	Federico A. Monzon, M.D.
Chief Executive Officer	Laurie S. Menser, CAE

The Finance Committee oversees AMP's financial affairs, including reviewing revenue & expense reports and recommending to the Board for approval an annual operating budget and the investment policy for the Association's assets.

AMP International Affairs Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair and Membership Affairs Liaison (Middle East)
Member (Southeast Asia)
Member and Brazilian Affiliate Coordinator
Member and Italy Affiliate Coordinator
Member (South Asia)
Member and Korea Affiliate Liaison (East Asia)
Member (Europe)
Member and India Affiliate Liaison (South Asia)
Member (South Asia)
Member and German Affiliate Coordinator
Member, Training & Educ Liaison and Brazilian Affiliate Coordinator
Advisor
Advisor
Member (*Ex Officio* – President)
Member (*Ex Officio* – Chief Executive Officer)

Rami Mahfouz, M.D.
Kenneth Chang, MBCHB
Renata A. Coudry, M.D., Ph.D.
Francesco Curcio, M.D.
Bibhu R. Das, Ph.D.
Jieun Kim, M.D., Ph.D.
Fernando Lopez-Rios, M.D.
Deepak Mishra, M.D.
Nikhil Patkar, M.D.
Nicole Pfarr
Roberta Sitnik, Ph.D.

Helen Fernandes, Ph.D.
Jin-Yeong Han, M.D., Ph.D.
Jane S. Gibson, Ph.D.
Laurie S. Menser, CAE

PURPOSE SUMMARY:

The International Affairs Committee (IAC):

- Enhances AMP as an international organization
- Promotes AMP's vision and mission internationally
- Facilitates international presence and participation in AMP groups and programs including AMP Europe and AMP Global
- Expands excellence in education and advocacy on behalf of patients, clinicians, and lab professionals to an international audience
- Enables the interaction of scientists and molecular pathologists in the various parts of the world
- Enhances AMP's international membership.

2025 ACTIVITIES:

- Approved and welcomed AMP's 10th International Affiliate member society: Korean Society for Genetic Diagnostics (KSGD) and AMP's 11th International Affiliate member society: Australasian Molecular Pathology Society (AMPS)
- Welcomed new AIPM Coordinator on the committee
- Hosted a webinar on Implementing DPYD testing to guide fluoropyrimidine dosing in cancer care in July 2025.
- AMP 2025 Annual Meeting Events:
 - Designed and released survey to collect data on the topic of Liquid Biopsy
 - This data was presented at the International Affairs Global Networking Lunch on Thursday and will be the focus of a companion webinar to be held in 2026.
- Selected International Trainee Travel Awardees from Canada and India and an IMPACT Awardee from Nigeria to attend the 2025 AMP Annual Meeting.
- IAC Committee represented by its Chair assisted in the planning, organization, and launching of the AMP Middle East 2025 in Abu Dhabi, UAE.
- Supported speakers for the Brazilian Society of Clinical Pathology & Laboratory Medicine (SBPC)'s annual congress and approved speaker support for the 12th Congress of the Molecular Pathology Association of India

AMP Membership Affairs Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair	Jennifer Morrisette, Ph.D.
Vice-Chair	Marco Leung, Ph.D.
Member	Barbara Anderson, M.S.
Member	Tejus Bale, M.D., Ph.D.
Member, Representative to Training & Education	Yang Cao, Ph.D.
Member	Filipe Cerqueira, Ph.D.
Member	Shuhua Cheng, Ph.D.
Member	Timothy Daniels, B.S.
Member	Kevin E. Fisher, M.D., Ph.D.
Member	Eitan Halper-Stromberg, M.D.
Member	Shuko Harada, M.D.
Member	Lisa Lansdon, Ph.D.
Member	Mariana Macedo, M.D., Ph.D.
Member, International Affairs Liaison	Rami Mahfouz, M.D.
Member	Rizwan Naeem, M.B.B.S
Member	Zehra Ordulu Sahin, M.D.
Member	Bijal Parikh, M.D., Ph.D.
Member	Honey Reddi, Ph.D.
Member	Jacquelyn Reuther, Ph.D.
Member	Sherin Shaaban, M.D., Ph.D.
Member	Marie Smithgall, M.D.
Member	Vibhuti Srivastava, Ph.D.
Member	David Suster, M.D.
Member	Panieh Terraf, Ph.D.
Member	Jessica Thomas, M.D.
Member	Cigdem Ussakli, M.D.
Member	Ying Wang, Ph.D.
Member	Shi Yang, M.D.
Member (<i>Ex Officio</i> – President)	Jane S. Gibson, Ph.D.
Member (<i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

PURPOSE SUMMARY:

The AMP Membership Affairs Committee (MAC) provides recommendations to the Board and assistance to other committees regarding matters of membership and professional development. The committee plays an important role in helping AMP respond to the needs of its members and in facilitating the development of leaders in the field of molecular pathology.

Ongoing Responsibilities:

- Assesses and makes recommendations that will enhance the professional development of AMP members and the benefits of AMP membership
- Provides regular and timely notification to members about opportunities for special projects within or outside of standing committees and subdivisions
- Facilitates leadership development for AMP through various initiatives such as the ad hoc and junior member volunteer process
- Receives requests from Chairs or Board for ad hoc members to work on projects and manages the volunteer application process

- Surveys member volunteers annually regarding their volunteer service experiences
- Surveys the membership periodically regarding how well their membership in AMP meets their needs and how well AMP is serving the needs of the profession
- Surveys non-members to help identify barriers to membership in AMP
- Conducts a member recruitment and retention program

2024-2025 Accomplishments

- Selected:
 - Two recipients for the AMP 2025 Technologist Travel Awards.
 - Three recipients of the AMP 2025 Trailblazer Travel Award.
- Planned and hosted:
 - 2025 AMP Annual Meeting First Timer's Lunch with a focus on understanding the needs of first-time attendees (in addition to providing information about AMP and the AMP Annual Meeting)
 - Three Innovation Spotlights: **(1) How to Get Involved with AMP at the AMP 2025 Annual Meeting.** Past AMP President, Laura Tafe and long-time member and volunteer Shelby Melton share their insights and experiences on getting on ballots for elected positions and serving in both elected and appointed volunteer positions. **(2) Transitioning Between Industry and Academia: Preparing for the Crosswalk** presented by Honey Reddi discussed what it takes to move careers between academia and industry. **(3) Project Management Strategies and Perspectives** by Naomi de Hart and William O'Callaghan explored differences in project management approaches between clinical settings and research settings.
- Developed committee member-driven projects to increase recruitment, retention, and member satisfaction. These projects include:
 - Followed up with 106 first-time lunch attendees from 2024 Annual Meeting **(Complete)**
 - Created a "Boston at-a-Glance" cheat sheet for first time meeting attendees **(Complete)**
 - Designed and distributed AMP First Timer's Lunch pens **(Complete)**
 - Worked with the Program Committee to enhance technologist specific content at the Annual Meeting **(Complete)**
 - Enhanced networking events at the Annual Meeting, including the Networking **(Complete)**
 - Fostering membership opportunities for trainees in low-income countries **(Ongoing)**
 - Creating a comprehensive suite of projects to inform and recruit trainees as part of the new free Associate Membership program **(Ongoing)**
 - Expanding AMP's micro-volunteer program so that everyone who wants to share their time and expertise with AMP has an opportunity to do so. **(Ongoing)**
 - Continuing the Member Spotlights project. **(Ongoing)**
 - Creating a PhD Reach Out project designed to make trainees in PhD programs aware of possible careers in the clinical space **(Ongoing)**
- Work closely with the International Affairs and Training & Education Committees to ensure that membership needs are met around the globe and through educational offerings. **(Ongoing)**

AMP Nominating Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair	Maria E. Arcila, M.D.
Genetics Subdivision Representative	Jane Houldsworth, Ph.D.
Genetics Subdivision Representative	Rachel D. Burnside, Ph.D., MBA
Hematopathology Subdivision Representative	Valentina Nardi, M.D.
Hematopathology Subdivision Representative	Pawel Mroz, M.D., Ph.D.
Infectious Diseases Subdivision Representative	Morgan A. Pence, Ph.D.
Infectious Diseases Subdivision Representative	Rachel Liesman, Ph.D.
Informatics Subdivision Representative	Jing Xu, M.D., Ph.D.
Informatics Subdivision Representative	Weiwei Zhang, Ph.D.
Solid Tumors Subdivision Representative	Jaclyn F. Hechtman, M.D.
Solid Tumors Subdivision Representative	Sinchita Roy-Chowdhuri, M.D., Ph.D.
Member (<i>Ex Officio</i> – President)	Jane S. Gibson, Ph.D.
Member (<i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

PURPOSE SUMMARY:

The AMP Nominating Committee is composed of the Past President (Chair) and two representatives from each subdivision. The chair and subdivision representatives are responsible for recruiting qualified AMP members to run for elected offices. A ballot is compiled and made available for voting by all current Regular AMP members. Voting for elected offices takes place during the month of May or June each year.

2025 ACTIVITIES:

The Nominating Committee nominated Officers and Committee Representatives for the 2025 annual elections.

AMP Professional Relations Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair	Eric Q. Konnick, M.D.
Vice Chair	Karen Weck, M.D.
Member	Esther Babady Otete, Ph.D.
Member (Infectious Disease Subdivision Rep.)	Heather Blakenship, Ph.D.
Member	David Bosler, M.D.
Member	Betsy Bove, Ph.D.
Member (AMP Rep. to FASEB Science Policy Committee)	Emilia Calvaresi, M.D., Ph.D.
Member (Solid Tumors Subdivision Rep.)	Jennifer Dien Bard, Ph.D.
Member (Genetics Subdivision Rep.)	Xiaoli Du, Ph.D.
Member (Hemepath Subdivision Rep.)	Andrea Ferreira-Gonzalez, Ph.D.
Member	Bryan Iorgulescu, M.D.
Member	Thủy Phùng, M.D., Ph.D.
Member	Dan Sabath, M.D., Ph.D.
Member (Informatics Subdivision Rep.)	Ryan Schmidt, M.D., Ph.D.
Member	Laura Tafe, M.D.
Member	Andria Del Tredici, Ph.D.
Member	Thao Truong, Ph.D., D(ABMM), M(ASCP)CM
Member	Oana Vele, M.D.
Member	Yaolin Zhou, M.D.
Junior Member	Sam Harvey, M.D., Ph.D.
Junior Member	Pamela Robertson, Ph.D.
Junior Member	Rosalie Sterner, M.D., Ph.D.
Committee Advisor	Jordan Laser, M.D.
Committee Advisor	Jill Murrell, Ph.D.
Member (<i>Ex officio</i> – President)	Jane S. Gibson, Ph.D.
Member (<i>Ex officio</i> – President-Elect)	Aaron Bossler, M.D., Ph.D.
Member (<i>Ex officio</i> – Past President)	Maria Arcila, M.D.
Member (<i>Ex officio</i> – EAC Chair)	Jay Patel, M.D., MBA
Member (<i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

PURPOSE SUMMARY:

The AMP Professional Relations Committee (PRC) is the primary liaison between AMP and other organizations for public policy issues other than reimbursement, which is the purview of the Economic Affairs Committee.

Major responsibilities of the Committee include:

1. Communicating and coordinating activities with the appropriate government offices, coalitions, trade associations, and patient and professional organizations to inform policy discussions that have an impact on the practice of molecular pathology;
2. Developing AMP positions on emerging policy issues affecting molecular pathology;
3. Interacting with a wide variety of entities, including other professional associations, Congress and U.S. Federal Agencies such as CMS, FDA, CDC, DHHS;
4. Advocating for policy changes in legislation and regulation that will advance the practice of molecular pathology.

The committee membership includes individuals employed in a variety of medical, scientific, institutional and commercial capacities.

2025 ACTIVITIES:

The PRC continues to monitor the activities of, and in some cases work with, federal agencies such as the U.S. Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) as well as policy committees such as the Roundtable on Genomics and Precision Health at the National Academies of Sciences, Engineering, and Medicine. After extensive discussion, the committee drafts AMP's policy positions and comments to federal agencies and members of Congress. AMP's government relations consultants, Jennifer Leib, Megan Anderson Brooks, and Lindsey Trischler of Innovation Policy Solutions, LLC (IPS), inform the Committee of all policy and legislative activity, assist in drafting policy positions, provide advice regarding advocacy strategies, and guide AMP's presence on Capitol Hill. IPS along with AMP Director of Public Policy and Advocacy, Annie Scrimenti and AMP Policy Manager, Samantha Pettersen, and when possible, Committee or other AMP members meet with congressional staff to educate them about issues relevant to molecular pathology, to offer AMP's expertise, and to advocate for AMP members' interests. (Note: As a 501c3 tax-exempt organization, AMP is prohibited from participating in any partisan activities and may not have a Political Action Committee (PAC). In addition, its direct and grassroots lobbying activities are limited per IRC 501h.)

AMP challenged the FDA's Final Rule on Laboratory Developed Testing (LDTs) in Court and WON!

In the spring of 2025, AMP argued in for the United States District Court Eastern District of Texas. The court case challenged the FDA's 2024 Final Rule treating laboratory-developed tests (LDTs) as medical devices subject to regulation under the Federal Food, Drug, and Cosmetic Act (FDCA). LDTs are diagnostic tests developed, validated, and performed internally by a clinical laboratory. Historically, they have been regulated under the Clinical Laboratory Improvement Amendments (CLIA), overseen by CMS, rather than by the FDA, although FDA has claimed jurisdiction for at least several decades. AMP argued that FDA lacks statutory authority under the FDCA to regulate these tests, and that the FDA's Final Rule was arbitrary, capricious, and/or exceeded its jurisdiction under the Administrative Procedure Act. The FDA countered that its revised definition of "in vitro diagnostic products" as stated in the Final Rule included tests developed within laboratories, and that the FDA's practice of enforcement discretion lets it phase in full device regulation.

The District Court ultimately held that the FDA's Final Rule **exceeded its statutory authority** under the FDCA and granted summary judgment to the plaintiffs. The court found that FDA's attempt to regulate laboratory services as devices is inconsistent with the text, structure, and history of the FDCA and CLIA, and that Congress never clearly authorized such a shift. The court concluded that, notwithstanding FDA's phased enforcement approach and carveouts, the rule must be vacated because it improperly asserts regulatory power over services rather than tangible medical "devices."

The court vacated and set aside the FDA's 2024 "Medical Devices; Laboratory Developed Tests" rule (89 Fed. Reg. 37,286), remanding the matter to the Secretary of Health and Human Services for further consideration. The court did not reach the plaintiffs' alternate claims (Count II), denied all other relief, and ordered the consolidated cases closed. The FDA did not appeal this decision and in September 2025 the U.S. Office of Information and Regulatory Affairs announced the official rescission of the Final Rule.

CLIA Clarification

AMP maintains the position that Laboratory Developed testing Procedures (LDPs) should remain under the authority of the Centers for Medicare and Medicaid Services (CMS), Clinical Laboratory Improvement Amendments (CLIA).

In 2023, the Regulatory Reform Task Force finalized a new CLIA Clarification Proposal to make changes to the current statute to reflect modern Molecular Pathology practices. The proposal definitively removes FDA

oversight of LDPs and does not include a risk classification system, but instead focuses on enhancing transparency and clarifying ambiguities in current regulation, i.e. defining performance characteristics, clinical and analytical validity, and enhances the proficiency testing program to ensure testing quality without the need for a premarket review process. AMP is dedicated to working with stakeholders and Congressional offices that continue to move this initiative forward to preserve a flexible system that fosters innovation as the most streamlined, cost-effective approach

In 2025 AMP met with numerous congressional offices to educate them on the benefits of CLIA clarification. Notably, AMP received interest from Rep. Debbie Wasserman-Schultz (D-FL) and Dr. Neal Dunn (R-FL) as potential sponsors of the bill. AMP met with nearly 40 Congressional offices to discuss this proposal.

Gene Patent Law

In 2025, AMP strongly advocated against The Patent Eligibility and Restoration Act, 2023 (S. 1546) which is an attempt to permit patents of genes, laws of nature and abstract ideas. This bill was introduced in both the senate and the house by Senator Coons (D-DE), Tom Tillis (R-NC) and Representatives Kevin Kiley (R-CA), Scott Peters (D-CA) on May 1st, 2025. This would revise Section 101 of the Patent Act, which defines patent eligibility. This states that PERA rescinds the *AMP v. Myriad* case, along with two other unanimously decided Supreme Court cases (*Alice Corp v. CLS Bank*, *Mayo Collaborative Services v. Prometheus Laboratories*) blatantly overturning the protection of DNA and other genetic sequences from becoming patent eligible. In response, AMP circulated a letter signed by over 90 stakeholders opposing PERA. On the Senate side, the bill's progression through the IP Subcommittee included a hearing held on October 8th. To combat this, AMP met with various offices in both the House and Senate to push back on the PERA and relay the devastating consequences it would have on patient access and scientific innovation.

Capitol Hill Happenings

AMP continues to foster existing partnerships on Capitol Hill. AMP Advocacy participated in over 25 congressional meetings in 2025 that focused on gene patent law, laboratory diagnostics legislation and regulation, AMP's CLIA Clarification proposal and the Protecting Access to Medicare Act (PAMA)/Saving Access to Laboratory Services Act (SALSA).

Patient Advocacy Group Engagement

In 2025, AMP carried out several patient advocacy initiatives. One key effort was the release of a new video in its Screening vs. Diagnostic Testing series, focusing on Hepatitis C testing. Alongside this launch, AMP also completed and released a Spanish-language translation of the video to improve accessibility and outreach. The Patient Engagement Subcommittee is currently working on the following projects:

- Patient series: "My Cancer Journey"
- "What is Liquid Biopsy?" video

Collaborations

AMP continues to participate in a wide-range of policy cooperations with other professional societies, laboratory groups, such as the National Academies of Sciences, Engineering, and Medicine (NASEM) Roundtable on Genomics and Precision Health (AMP representative **Dr. Vicky Pratt**), Federation of American Societies for Experimental Biology (FASEB) (AMP representative **Dr. Emilia Calvaresi**), and the Personalized Medicine Coalition (PMC), Cancer Leadership Council, Coalition for Innovation Lab Testing, Laboratory Access and Benefits (LAB) Coalition.

AMP Program Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair	Somak Roy, M.D.
Chair-Elect	Annette Kim, M.D., Ph.D.
Genetics Subdivision Representative	Stuart A. Scott, Ph.D.
Genetics Subdivision Representative	Sherin Shaaban, M.D., Ph.D.
Hematopathology Subdivision Representative	Amir Behdad, M.D.
Hematopathology Subdivision Representative	Joanna Conant, M.D.
Infectious Diseases Subdivision Representative	Ryan R. Relich, Ph.D.
Infectious Diseases Subdivision Representative	Anisha Misra, Ph.D.
Informatics Subdivision Representative	Heather Blankenship, Ph.D.
Informatics Subdivision Representative	Priya Velu, M.D., Ph.D.
Solid Tumors Subdivision Representative	Arivarasan Karunamurthy, M.D.
Solid Tumors Subdivision Representative	Fei Dong, M.D.
Technical Topics Representative	Tessara Baldi, B.S.
Technical Topics Representative	Timothy Daniels, B.S.
Member (<i>Ex Officio</i> – President)	Jane S. Gibson, Ph.D.
Member (<i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

PURPOSE SUMMARY:

The Program Committee is responsible for overall planning and organization of the AMP Annual Meeting, including sessions and abstracts/posters. In addition, the Committee selects the winners of the Technologist Poster Awards.

2025 ACTIVITIES:

Planned and moderated the sessions for the 2025 Annual Meeting & from November 11-15, 2025, to be held in Boston, MA, USA, along with the recorded content that will be available in January 2026.

AMP Publications Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair	Patricia Tsang, M.D., MBA
<i>JMD</i> Editor-in-Chief	Ronald M. Przygodzki, M.D.
Member	Yogesh Chander, Ph.D.
Member	Annacarina Fabiana Lucia da Silva, M.D.
Member	Midhat S. Farooqi, M.D., Ph.D.
Member	Juehua Gao, M.D., Ph.D.
Junior Member	Patricia Hernandez, M.D.
Member	Arivarasan Karunamurthy, MBBS, M.D.
Member	Madhu M Ouseph, M.D., Ph.D.
Member	Thuy L. Phung, M.D., Ph.D.
Member	Daniel Sabath, M.D., Ph.D.
Member	Zheng Jin Tu, Ph.D.
Member	Barbara A. Zehnbauer, Ph.D.
<i>JMD</i> Managing Editor	Emily Essex
Member (<i>Ex Officio</i> – President)	Jane S. Gibson, Ph.D.
Member (<i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

PURPOSE SUMMARY: Members of the Publications Committee are appointed by the Board to serve up to six (6) two-year, renewable terms, and a junior member to serve a two-year term.

- The Publications Committee has certain responsibilities for AMP's official journal, *The Journal of Molecular Diagnostics (JMD)*, which is co-owned by the American Society for Investigative Pathology (ASIP), including advisory to AMP's Board and ASIP's Council regarding *JMD* policy issues; scope statement; business success; publisher Request for Proposal and selection; selection of Editors and Editorial Board members; performance expectations for Editors.
- The Publications Committee does not oversee *JMD*'s production or editorial functions; however, it may request or receive information and make recommendations to the Editor-in-Chief and Managing Editor.
- The Committee reviews AMP member submissions of Case Reports for potential publication in *CAP Today*.
- The Committee holds a virtual meeting monthly, meets face-to-face before the annual meeting, and communicates electronically throughout the year.

2025 ACTIVITIES:

- Reviewed and evaluated AMP Case Reports submissions for potential publication in *CAP Today*.
- Launched an initiative for Early Bird Case Studies to be considered for publication as a Case Report in *CAP Today* in collaboration with AMP's Training & Education Committee
- Formed a task force to assess Elsevier's contract renewal proposal related to *JMD*.
- Participated in the analysis of recent *JMD* survey responses from key stakeholders to provide data-driven feedback on the Elsevier contract proposal to the AMP Board.
- Identified and recommended key *JMD* articles monthly to feature in the *AMPLifications* newsletter.
- Created a list of potential topics and authors for *JMD* review articles, guest editorials, spotlight features, and the recent Silver Anniversary Edition issues.
- Periodically reviewed and updated the AMP Wikipedia page to ensure accuracy and relevance.

AMP Case Report authors published in *CAP Today* since November 2024

Title	Corresponding Author	Co-authors
<i>Evaluation of the genetic findings in B-cell lymphoma in the context of clinicopathological data</i>	Alexander Gross, M.D. Vanderbilt University Medical Center Nashville, TN, USA	<ul style="list-style-type: none"> • Hamama Bushra, M.D. • Emily Mason M.D., Ph.D. • Nico Lopez-Hisijos, M.D. • Rebecca B. Smith, Ph.D. • Laura A. Lee M.D., Ph.D. • Nelson Barbara, Ph.D. • Ashwini Yenamandra, Ph.D.
<i>A 67-Year-Old Female with Rare Intracranial Mesenchymal Tumor Featuring the EWSR1::CREM Fusion Gene</i>	Dong Zhang, Ph.D. New York Institute of Technology College of Osteopathic Medicine Old Westbury, NY, USA	<ul style="list-style-type: none"> • Rachel Radigan, MPH • Alexa Finkelstein, BS • Tejus A. Bale, M.D., Ph.D. • Michael Zaidinski, BS • Marc K. Rosenblum, M.D. • Maria Plummer, M.D. • Wallace Chan, M.D.
<i>Identifying the Signal in the Signal: Incidental Detection of B-cell Lymphoproliferative Disorder Related Variants in the Molecular Profiling of a Spindle Cell Sarcoma</i>	Adam Fisch, M.D., Ph.D. Massachusetts General Hospital / Harvard Medical School Boston, MA, USA	<ul style="list-style-type: none"> • Ting Zhao, M.D. • Robert P. Hasserjian, M.D., Ph.D. • Ivan A. Chebib, M.D., MS
<i>Germline Variant Not Present in Tumor?</i>	Daniel J. Mettman, M.D. Kansas City Veterans' Affairs Medical Center Kansas City, MO, USA	<ul style="list-style-type: none"> • Sobrina Mohammed, M.D.

Requests from the Publications Committee

- We encourage AMP members to serve as reviewers for the *Journal of Molecular Diagnostics*. Please [register an account](#) on the JMDI Editorial Manager platform and enter applicable expertise terms/keywords to your profile. AMP membership is not required.
- We encourage AMP members to submit Case Reports for potential publication in *CAP Today*. More information about the program and online submission portal is available on our [website](#).

AMP Strategic Opportunities Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair	Aaron D. Bossler, M.D., Ph.D.
Board Member	Yasmine M. N. Akkari, Ph.D.
Member	Estevan Kiernan, MS
Member	Jordan Laser, M.D.
Member	Federico A. Monzon, M.D.
Member	Nirali M. Patel, M.D.
Advisor	Anthony N. Sireci, M.D., M.S.
President (<i>Ex Officio – President</i>)	Jane S. Gibson, Ph.D.
Chief Executive Officer (<i>Ex Officio – Chief Executive Officer</i>)	Laurie Menser, CAE

PURPOSE SUMMARY: The Strategic Opportunities Committee (SOC) assesses the opportunities and challenges in the molecular pathology profession and other environments that affect AMP interests, including:

- assessing trends and activities in the broad environment external to AMP, *i.e.*, "horizon scanning"
- identifying and assessing external threats that could prevent AMP from attaining its goals
- identifying and assessing external opportunities that can help AMP attain its goals
- identifying organizations for potential relationships that can help AMP attain its goals

It also advises, conducts research for, or provides information to the Board as requested.

AMP Training and Education Committee Annual Report, 2025

COMMITTEE MEMBERS:

Chair	Marjorie David, M.D.
Genetics Subdivision Representative	Sara Akhavanfard, M.D., Ph.D.
Genetics Subdivision Representative	Madina Sukhanova, Ph.D.
Hematopathology Subdivision Representative	Kevin Fisher, M.D., Ph.D.
Hematopathology Subdivision Representative	Richard Wong, M.D., Ph.D.
Infectious Diseases Subdivision Representative	Rebecca Yee, Ph.D.
Infectious Diseases Subdivision Representative	Rebekah Dumm, Ph.D.
Informatics Subdivision Representative	Eric Klee, Ph.D.
Informatics Subdivision Representative	Robert Bell, M.D.
Solid Tumors Subdivision Representative	Brett Baskovich, M.D.
Solid Tumors Subdivision Representative	Erica Vormittag-Nocito, M.D.
Junior Member	Alexander Neil, M.D., Ph.D.
Junior Member	Ashley Barlev, M.D., Ph.D.
Medical Technologist Member	Barbara Anderson, Ph.D.
Medical Technologist Member	Krupa Jani, M.S.
Membership Affairs Committee Liaison	Yang Cao, Ph.D.
International Affairs Committee Liaison	Roberta Sitnik, Ph.D.
Member (<i>Ex Officio</i> – President)	Jane S. Gibson, Ph.D.
Member (<i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

PURPOSE SUMMARY:

The Training and Education (T&E) Committee is comprised of representatives from each of AMP's subdivisions: genetics, hematopathology, infectious diseases, informatics, and solid tumors as well as technologist representatives, junior members, and liaisons from the International Affairs and Membership Affairs Committees (IAC and MAC). It oversees important issues such as education and certification in molecular pathology and mentoring of trainees, as well as developing educational programs for different audiences.

2025 ACTIVITIES:

AMP 2025 Annual Meeting & Expo Activities:

2025 GetAMPed! Updates and Case Studies in Molecular Pathology:

The T&E Committee planned and taught an in-person course for the AMP 2025 Annual Meeting & Expo on November 12th. The course was taught twice as 3.5-hour long sessions with a focus on variant interpretation tools, dPCR for MRD, and validation of methylation classifiers. The course included four interactive case study break-out sessions which enabled participants to apply what they learned to cases in infectious diseases, solid tumors, hematopathology, and genetics.

Early Bird Sessions at the Annual Meeting & Expo - Case Studies Presented by Trainees or Technologists:

The T&E Committee hosted an opportunity for fellows, residents, postdocs, graduate students, or technologists to present an interesting and/or challenging case study for the AMP 2025 Annual Meeting and Expo. This year, due to an unprecedented number of applicants, 4 additional early bird case studies were selected to present at the innovation spotlight stages. Trainee/Technologist presenters in 2025 are listed below:

<i>Case Studies in Genetics</i>	SORD Mystery Solved with Long Read Sequencing	Irfan Yasin, MBBS	University of Minnesota
	Dual Balanced Insertions on Chromosome 2 Identified in a Carrier Mother: Implications for Recurrent Copy Number Variants in Offspring	Parisa Kargaran, Ph.D.	Mayo Clinic
	Paired Tumor-Normal Sequencing Identifies a Homozygous Pathogenic BRCA2 Germline Variant Leading to a Diagnosis of an Atypical Presentation of Fanconi Anemia	Andrew Lingard, M.D., MSc	University of Ottawa / The Ottawa Hospital
	Homozygosity for the SMN2 c.859G>C allele accounts for the phenotypic and genotypic discordances seen in an uncommon case of spinal muscular atrophy revealed by newborn screening	Adriel Kim, Ph.D.	The Ohio State University
<i>Case Studies in Hematopathology</i>	Resolving Amplicon Originated T-cell Receptor Clonotypes Using Anchor Multiplexed PCR	Monica Miyakawa-Liu, M.D.	Stanford University
	Optical Genome Mapping Uncovers Disease-Defining Variants in an Adult T-lymphoblastic Leukemia and Impacts Prognosis	Amanda Maxfield, BA	Geisel School of Medicine at Dartmouth
	Interstitial Deletions of 11q: Rare class of non-canonical KMT2A fusion?	Jonathan Young, M.D., Ph.D.	Mass General Brigham
	Beyond the Classics: The Spectrum of NPM1 Mutations	Ling-Lin Pai, M.D., Ph.D.	Hospital of the University of Pennsylvania
	Discordance of FLT3-ITD mutation testing in Acute Myeloid Leukemia between specimens: a discussion of prognosis implications and reporting options	Nea Fride, M.D.	University of Wisconsin Madison
	High-Grade B-Cell Lymphoma with 11q Aberration: A Near Miss	Ifeoluwatomi Fuwape, M.D.	Duke University Hospital System
<i>Case Studies in Infectious Diseases</i>	Identification of Streptococcus intermedius associated with culture-negative brain abscesses and meningoenophalitis through CSF metagenomic sequencing	Jay Patel, MBBS	Wellspan Chambersburg Hospital
	Cross-reactivity of Streptococcus species with the Enterococcus assay of the Biofire FilmArray Blood Culture Identification (BCID) panel	Jeffrey Pacheco, BS	Lenox Hill Hospital
	Burned by Persistent Fever: A Case of Acute Coxiella burnetii Infection	Ayesha Sundaram, M.D.	Montefiore Medical Center
	CNS Co-infection with Aspergillus terreus and Varicella-Zoster Virus Identified by Metagenomic Next-Generation Sequencing in an Immunocompromised Host	Kurt Koehler, M.D.	Hospital of the University of Pennsylvania
<i>Case Studies in Solid Tumors</i>	<i>Both DNA Methylation and RNAseq were Necessary to Diagnosis an Intracranial Sarcoma</i>	Christina Ferrone, Ph.D.	National Cancer Institute (NCI) / National

			Institutes of Health (NIH)
	A Surprise Case of Familial Biparental Hydatidiform Mole	Samuel Harvey, M.D., Ph.D.	Johns Hopkins
	Detection of MYBL1 Rearrangement as a Diagnostic Hallmark in Diffuse Astrocytoma Through Integrated Copy Number and Structural Variant Calling	Ege Cubuk, M.D.	Baylor College of Medicine
	Undifferentiated Epithelioid and Spindle Cell Neoplasm of the Uterus Harboring SMARCA2::CREM fusion: Exploring the Spectrum of the New Entity	Kanako Okamoto, M.D.	University of Alabama at Birmingham
	When the BRAF Isoform is and isn't an Isoform	Brian Nguyen, M.D.	University of Colorado Anschutz Medical Campus
	Clash of Classifiers	Sunny Lu, M.D.	University of Calgary
	Synchronous Lung Adenocarcinomas with Unique MET Exon14 Skipping Alterations in a Patient with Pathogenic Germline NBN Variant	Jonathan Willner, M.D.	Memorial Sloan Kettering Cancer Center
	The Molecular Footprint of Temozolomide: A Genomic Signature Unmasking the Origin of a Secondary Renal Cell Carcinoma	Ting Zhao, M.D.	Mass General Brigham
	A Tale of Two Targetable Fusions: Navigating Dual Driver Events in Lung Adenocarcinomas	Tasnuva Rashid, M.D., Ph.D.	MD Anderson Cancer Center
	"Mimicry in the Posterior Fossa: Ependymoma-Like Medulloblastoma Revealed by Methylation Profiling"	Tasleem Banu, M.D.	Westchester Medical Center

The Molecular Genetic Pathology Fellowship Program Directors (MGP PD) Council

The MGP Program Directors (MGP PD) Council consists of Bijal Parikh (Chair), Jadee Neff (Chair-Elect), and Noah Brown (Past-Chair). Kevin Fisher acts as the T&E committee representative to this group. The MGP PD Council facilitates the discussions of the MGP Program Directors Working Group and responds to the ABP and ACGME on matters related to MGP Fellowship programs. This year, they successfully completed the first NRMP Fellowship Match Recruitment for 2026-2027. The MGP program directors met at the AMP 2025 Annual Meeting & Expo, to discuss the continuation of the match process.

The Education Community of Practice (EdCoP) Group

The AMP Education Community of Practice Group is lead by Thomas Lee with working group members Yang Cao, Lulu Sun, and Erica Vormittag-Nocito. In 2025, the working group began the task of mapping educational resources to core competencies identified in molecular pathology curriculum manuscripts. The EdCoP group held a meeting at the AMP Annual Meeting and Expo discussing methods for integrating bioinformatics education into clinical and laboratory training and will be hosting a webinar called "Effective communication techniques for educators".

Innovation Spotlight Stages

The T&E Committee hosted two Innovation Stages. One on the soon-to-be-launched pilot of the AMP mentorship program and another on “How to Give a Job Talk.”

Trainee Networking Luncheon

Trainees were invited to connect with fellow trainees and other members of AMP while enjoying casual conversation and fun informal trivia. The event closed with a book drawing.

Technologist Networking Luncheon

The luncheon was a social opportunity to share working and learning experiences with others in the field of laboratory technology.

Other 2025 T&E Activities:

2025 Live Webinars and Recorded Online Content (ROCs):

Date	Speaker	Title	NOTES (Registrants/Attendees)
Major Initiative: <u>Emerging and Evolving Biomarkers: Recent Findings, Laboratory Considerations, and Clinical Implications</u>			
1/30/25	Diana Mandelker	Germline Testing in Cancer Patients: Molecular Diagnostic Considerations and Clinical Implications	793/340
4/1/25	Constance Bär	Molecular International Prognostic Scoring System (IPSS-M) in Routine Diagnostics	379/229
6/26/25	Biagio Ricciuti	STK11 and KEAP1 Mutations in Lung Cancer	494/238
10/9/25	Tejus A. Bale	Cell-free DNA (cfDNA) from Cerebrospinal Fluid (CSF) for Diagnosis and Molecular Testing of Brain Tumors	<i>Not available as of the date of this report.</i>

Date	Speaker	Title	NOTES (Registrants/Attendees)
Major Initiative: HR+/HER2- Breast Cancer Educational Series			
10/21/25	Katherine Geiersbach, Karthik Giridhar, Shuko Harada, Eric Vail, Paul Waring	Current Concepts in Molecular Testing for HR+/HER2- Metastatic Breast Cancer	<i>Not available as of the date of this report.</i>
10/27/25	Katherine Geiersbach, Karthik Giridhar, Shuko Harada, Eric Vail, Paul Waring	Current Concepts in Molecular Testing for HR+/HER2- Metastatic Breast Cancer	<i>Not available as of the date of this report.</i>
10/30/25	Katherine Geiersbach, Karthik Giridhar, Shuko Harada, Eric Vail, Paul Waring	Current Concepts in Molecular Testing for HR+/HER2- Metastatic Breast Cancer	<i>Not available as of the date of this report.</i>

<i>Date</i>	<i>Speaker</i>	<i>Title</i>	<i>NOTES (Registrants/Attendees)</i>
Webinar Series: Horizons			
1/21/25	Stephanie Chrysanthou	Nanopore sequencing: A fourth-generation sequencing technology	466/280
7/24/25	Kritika Krishnamurthy, Lucas Osborn	Advancing Clinical Diagnostics with Rapid and Automated Next-generation Sequencing Workflows	284/206
9/3/25	Sanjat Kanjilal, Adrian Egli	Harnessing Artificial Intelligence for Infectious Disease Diagnostics	132/81
9/30/25	Srikar Chamala	From Variants to Value: The Expanding Role of Clinical Bioinformatics	249/133
Webinar Series: Horizons; Clinical Practice Webinars			
5/22/25	Julie W Hirschhorn	Considerations for SARS-CoV-2 Genomic Surveillance	196/92
10/16/25	Jane Gibson	Developing Consensus for a More Provider-Friendly Next Generation Sequencing Molecular Biomarker Report	<i>Not available as of the date of this report.</i>
Webinar Series: Trainee and Early Career Series			
7/8/25	Jessica Williams, Stephanie Siegmund, Katherine Morgan, Kenneth Ofori (moderator: Zachary Coty-Fattal)	MGP Board Prep	445/126
9/9/25	Igor Odintsov, Marie Smithgall, Katarzyna Thompson, Grace Weber	Optimizing Your Fellowship in Molecular Pathology	271/121
Education Community of Practice (EdCoP)			
01/2026	Vijayalakshmi Ananthanarayanan, Bijal Parikh, Alexander Neil	Adapting Communication Strategies for Today's Pathology Learners	<i>Not available as of the date of this report.</i>

Online Education - AMPED™:

The T&E Committee and staff have designed and developed educational materials for populating educate.amp.org. The AMP learning management system (LMS), AMPED™, attracted close to 4,000 active users in 2024 (January 2024-December 31, 2024) where 56% of the users were non AMP members and about 35% from outside of the US.

- **Course Bundles/AMP Certificate Programs:** Courses are live programs that were recorded and translated to a self-paced online course. Certificate programs are self-paced on-demand content designed to provide a deep dive on specific areas of interest. New courses and certificate programs launched in 2025 include:
- Current Concepts in Molecular Testing for HR+/HER2- Metastatic Breast Cancer

- **AMP Flashcards**: We currently have 5 flashcards sets available on AMPED™ The cards can also be used as study aids for ASCP certification exams. In addition, there are four more sets available: 1) [multiple myeloma](#), 2) [colorectal cancer](#) 3) [acute myeloid leukemia](#), 4) [Technologist in Molecular Biology: Laboratory Operations](#), and 5) [Technologist in Molecular Biology: Molecular Techniques](#)
- **FISE Question Bank**: This is the eighth year of a continuing collaboration with the MGP-PD Council to provide fellows with a Fellowship In-Service Examination (FISE) at the beginning and at the end of their fellowship year. Additional FISE exam questions were written by MGP faculty and reviewed by the T&E, the bank currently consists of >550 questions. New this year, learners receive 75 randomly selected questions with a breakdown that more closely matches the Board exam format. AMP staff provides non-attributed results to participating institutions at the beginning of the fellowship year (in October) and at the end of the year (in May/June).
- **Molecular in a Minute**: Since its initiation in 2021, the T&E Committee completed 15 microlearning modules called Molecular in a Minute. There are plans to add an additional 2 and to increase its visibility by using AMP's social media accounts.
- **Molecular-in-My-Pocket™ cards**: The T&E Committee is continuously expanding the Molecular-in-My-Pocket™ reference card collection. One new card ([Neuropathology](#)) was created. The T&E has also made substantial edits to many of the cards. Cards are reviewed annually by the Assessment Content Editing Group (under the purview of the T&E Committee) for accuracy and for any required updates. There have been more than 3,500 user visits to the MIMP card homepage from 11/2024 - 4/2025.
- **Molecular Genetic Pathology Review Course**: In May 2025, the Molecular Genetic Pathology Review course was held as a 5-day virtual-live course. With 16 molecular genetic pathology expert faculty speaking on topics ranging from molecular technologies, test validations and statistics, molecular oncology, infectious diseases and more, the course was designed to assist attendees in preparing for the MGP subspecialty certification exam as well as other exams in molecular pathology. This course was recorded and posted as a self-paced on demand course.

Educational Partnerships/Collaborations, Co-Sponsorships, Companion Meetings:

United States and Canadian Academy of Pathology (USCAP) March 2025 – Boston, MA

The AMP 2025 Companion Society Symposium,

“Insights into Developing and Implementing a Germline Molecular Profiling Assay and Workflow for Neoplastic Disease”, was co-moderated by Adam S. Fisch, M.D., Ph.D. and Lu Wang, M.D., Ph.D.

Speakers were:

- Jonathan Nowak, M.D., Ph.D.
- Diana Mandelker, M.D., Ph.D.
- Kim E. Nichols, M.D.

American Society for Clinical Pathology (ASCP) November 2025 – Atlanta, GA

“Association for Molecular Pathology (AMP) Companion Society Session: Too Much of a Good Thing? Navigating the Complexities of Molecular Microbiology Results”, presented by Rebecca Yee, Ph.D.

AMP Subdivision Leadership Annual Report, 2025

SUBDIVISION LEADERSHIP

	Genetics	Hematopathology	Infectious Diseases	Informatics	Solid Tumors
Chair	Kristy Crooks	Rena Xian	Joseph D.C. Yao	Julie Hirschhorn	Anthony N. Snow
Clinical Practice Committee	Jennifer Laffin	Susan Harley	Meghan Starolis	Thomas D. Lee	Lauren Ritterhouse
	Molly Schroeder	Peng Wang	Mark D. Gonzalez	Andrea Sboner	Nikoletta Sidiropoulos
Economic Affairs Committee	Victoria Pratt	Patricia Tsang	Joseph Yao	Nick Bevins	Heather Williams
Nominating Committee	Jane Houldsworth	Valentina Nardi	Morgan Pence	Jing Xu	Jaclyn F. Hechtman
	Rachel D. Burnside	Pawel Mroz	Rachael Liesman	Weiwei Zhang	Sinchita Roy-Chowdhuri
Professional Relations Committee	Xiaoli Du	Andrea Ferreira Gonzalez	Heather Blankenship	Ryan Schmidt	Bryan Iorgulescu
Program Committee	Stuart Scott	Amir Behdad	Ryan Relich	Heather Blankenship	Arivarasan Karunamurthy
	Sherin Shaaban	Joanna L. Conant	Anisha Misra	Priya Velu	Fei Dong
Training & Education Committee	Sara Akhavanfard	Kevin Fisher	Rebecca Yee	Eric Klee	Brett Baskovich
	Madina Sukhanova	Richard Wong	Rebekah Drumm	Robert C. Bell	Erica R. Vormittag-Nocito
Junior Member	Husnain Ali	Muhammad Hussain	Mohanad Albayyaa	Ratilal Akabari	Pankaj K. Ahluwalia

PURPOSE SUMMARY:

The Subdivision Leadership (SL) consists of a Chair, representatives to the Clinical Practice, Economic Affairs, Nominating, Program, Professional Relations, Training & Education Committees, and *ad hoc* representatives to the Subdivision Leadership groups from the Professional Relations and Economic Affairs Committees. Subdivision Chairs are responsible for the successful operation and development of the subdivision that they lead.

Each Subdivision Leadership group meets quarterly and functions in an AMP advisory panel of discipline-specific subject matter experts convened to address issues of importance to their Subdivision. They carry out their subdivision leadership responsibilities by:

- Assessing the needs and priorities of the Subdivision membership and the broader discipline.
- Offering feedback on relevant initiatives to the Clinical Practice Committee, Training and Education Committee, and other appropriate groups.
- Contributing ideas and recommendations for content at the Annual Meeting and other AMP educational events.
- Supporting the identification and nomination of prospective AMP volunteers and future leaders.
- Serving as a resource for advocacy efforts and related initiatives.

2025 ACTIVITIES:

All Subdivision Leadership groups contributed to the biannual *Subdivision Spotlight* email digests, highlighting AMP initiatives and *JMD* articles aligned with their members' interests. Additionally, each group authored a guest editorial for *JMD*'s Silver Anniversary Edition, offering expert perspectives on the current landscape and future direction of their respective Subdivisions. Provided Advocacy with the review of The Precision Medicine Coalition's (PMC) AI policy. Participated and contributed to projects related to the different AMP Committees.

Genetics - Served as AMP's internal genetics advisory board, guiding initiatives in clinical practice, advocacy, and education. The group addressed key issues in genetics, including variant interpretation and classification, next-generation sequencing, pharmacogenomics, standards for whole genome and exome sequencing, forensic applications, and enhancing diversity in genomic databases. Reviewed draft consensus statements from the October 2024 STRIPE (Standardizing Laboratory Practices in Pharmacogenomics) Conference, aimed at advancing standardization in PGx. Additionally, provided confidential feedback on a prepublication manuscript supporting pharmacogenomics guideline development for the UK NHS.

Hematopathology - Served as AMP's internal advisory board for hematopathology, supporting the development of initiatives in clinical practice, advocacy, and education. The group addressed emerging issues in molecular hematopathology, including translational research in myelomas, minimal residual disease (MRD) monitoring in hematologic malignancies, next-generation sequencing (NGS), and immunology. Explored which AMP committees were best suited to address key issues and emphasized how guideline development can support advocacy efforts, including billing code changes. The group also reviewed challenges related to NGS billing and documentation, including the potential value of genomic consults in clinical reporting.

Infectious Diseases - Served as AMP's internal advisory board for infectious diseases, contributing to the development of initiatives in clinical practice, advocacy, and education. Addressed key issues in clinical molecular diagnostics, including next-generation sequencing (NGS), artificial intelligence and machine learning, antimicrobial resistance, measles, and the microbiome. Supported the maintenance of AMP's resource webpages for emerging infectious diseases, including SARS-CoV-2, Mpox, H5N1 avian influenza, and measles. Provided feedback to the FDA on draft guidance regarding the validation of certain in vitro diagnostic devices for emerging pathogens during a Section 564-declared public health emergency.

Informatics - Served as AMP's internal advisory board for informatics, supporting the development of initiatives in clinical practice, advocacy, and education. Addressed key topics including the development of bioinformatics pipelines for clinical next-generation sequencing (NGS), informatics tools in metagenomics, and electronic health record (EHR) interoperability for clinical genomics data. Provided the Training & Education Committee with feedback on an educational resource aimed at helping residents and fellows perform tertiary analysis of NGS reports. Contributed input to the Advocacy Committees in response to Elevance's request to review a non-coverage policy and accompanying questionnaire regarding the medical necessity of AI-based predictive pathology models.

Solid Tumors - Served as AMP's internal advisory board for solid tumors, contributing to the development of initiatives in clinical practice, advocacy, and education. Addressed current issues in the clinical management of cancer, including the application of circulating tumor cells, gene fusions, homologous recombination deficiency (HRD), liquid biopsies, tumor mutational burden, and related biomarkers. Identified oncology-related clinical practice areas requiring additional expert guidance. Provided the Economic Affairs Committee (EAC) with expert review of a draft Local Coverage Determination (LCD): *MoIDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis*. Also supported AMP's advocacy efforts through review of the Precision Medicine Coalition's (PMC) draft policy on artificial intelligence.

Requests from the Subdivision Leadership

- We encourage all AMP members to alert their Subdivision Chair or Representatives to current or emerging specific needs that AMP should consider and address.
- We encourage AMP members to actively contribute to requests for information from their respective Subdivision Leadership.
- We encourage AMP members to serve as reviewers for the *Journal of Molecular Diagnostics*. Please [register an account](#) on the JMDI Editorial Manager platform and enter applicable expertise terms/keywords to your profile. AMP membership is not required.